Clinical Trial Update: A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours [Phase 1]

View source ↗

Summary

A Phase I multiple ascending dose study of ASLAN002 in adults with advanced or metastatic solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• ASLAN002

Snippet

Sponsor: ASLAN Pharmaceuticals | Conditions: Malignant Solid Tumour | Phase 1 | Status: COMPLETED